EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY 4.0

Advancing Influenza Prevention: The Case for Pre-Exposure Prophylaxis (PrEP)

Hanumantha Rao Paritala, Luis Mier-Y-Teran-Romero, Ramya Natarajan, Peter Adams, Cassandra Spector, Katherine Topf, Ashwin Kadambi, Julia A Falvey iD, Mark J Lamias iD, David P Durham iD, Kimberly Armstrong

Vaccines · 30.07.2026 · 14 (8) · 666

DOI: 10.3390/vaccines14080666 ↗

Kurz gefasst

Kommentar in der Zeitschrift Vaccines, online erschienen am 30.07.2026. Verfasst von Hanumantha Rao Paritala und 10 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Hea…. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Oak Ridge Institute for Science and Education, U.S. Department of Energy, U.S. Department of Health and Human Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Influenza remains a significant national health security threat, particularly for vulnerable populations, as existing control measures do not fully mitigate its impact. This gap in protection is especially pronounced early in a pandemic when a well-matched vaccine may not yet be available, as well as in populations unable to mount an optimal vaccine response. Clinical studies support pre-exposure prophylaxis (PrEP) therapeutics as a promising complementary strategy to reduce influenza transmission and disease severity, potentially easing the strain on healthcare systems during outbreaks. This manuscript outlines the Biomedical Advanced Research and Development Authority’s (BARDA’s) target product profile (TPP) for a long-acting influenza PrEP product, reviews the current development landscape, and models the potential impact of early PrEP product deployment using agent-based modeling in a synthetic population of 19.5 million people across pandemic scenarios resembling the 1918, 1968, and 2009 influenza pandemics. Simulations showed that early deployment of a 70%–effective PrEP reduced cumulative and peak infections, delayed the epidemic peak, and provided the greatest benefit in less transmissible pandemics; at 40–50% coverage, PrEP fully mitigated a 2009-like pandemic and substantially reduced transmission in 1918- and 1968-like scenarios. The TPP defines key characteristics of an effective PrEP option for seasonal and pandemic influenza that (1) demonstrates a strong safety and tolerability profile across all populations; (2) targets a direct-acting antiviral mechanism of action; (3) reduces the relative risk of symptomatic influenza infection by at least 70% in an unvaccinated population and (4) provides single-dose, season-long protection to optimize patient adherence. In this context, integrating PrEP into influenza prevention strategies could improve control of virus spread, strengthen protection for high-risk groups, and significantly reduce the overall public health impact of seasonal and pandemic influenza.

Schlagwörter

Stichwörter der Autor:innen

PrEPagent-based modelingantiviralschemoprophylaxisinfluenza PrEPinfluenza pre-exposure prophylaxislong-acting antiviralsmedical countermeasurespandemic preparednesstarget product profile

Autor:innen und Institutionen

  • Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS), Washington, DC 20024, USA.
  • Leidos, Supporting the Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS), Washington, DC 20…
  • Oak Ridge Institute for Science and Education, Supporting the Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and…
  • Booz Allen Hamilton, Supporting the Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS), Wash…

ORCID-Profile: Julia A Falvey, Mark J Lamias, David P Durham

Förderung

  • Oak Ridge Institute for Science and Education
  • U.S. Department of Energy
  • U.S. Department of Health and Human Services

Zitieren

APA

Paritala, H. R., Mier-Y-Teran-Romero, L., Natarajan, R., Adams, P., Spector, C., Topf, K., Kadambi, A., Falvey, J. A., Lamias, M. J., Durham, D. P., & Armstrong, K. (2026). Advancing Influenza Prevention: The Case for Pre-Exposure Prophylaxis (PrEP). Vaccines, 14(8), 666. https://doi.org/10.3390/vaccines14080666

Vancouver

Paritala HR, Mier-Y-Teran-Romero L, Natarajan R, Adams P, Spector C, Topf K, et al. Advancing Influenza Prevention: The Case for Pre-Exposure Prophylaxis (PrEP). Vaccines. 2026;14(8):666. doi:10.3390/vaccines14080666

BibTeX
@article{Paritala2026,
  author = {Paritala, Hanumantha Rao and Mier-Y-Teran-Romero, Luis and Natarajan, Ramya and Adams, Peter and Spector, Cassandra and Topf, Katherine and Kadambi, Ashwin and Falvey, Julia A and Lamias, Mark J and Durham, David P and Armstrong, Kimberly},
  title = {Advancing Influenza Prevention: The Case for Pre-Exposure Prophylaxis (PrEP)},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {8},
  pages = {666},
  doi = {10.3390/vaccines14080666}
}
Kostenlos starten →